2 results
Approved WMOCompleted
Primary:* To determine the efficacy of PSI-7977 in combination with RBV administered for 12 weeks compared with PEG/RBV administered for 24 weeks in treatment-naïve patients with HCV genotype 2 or 3 as assessed by the rate of SVR12 (HCV RNA of…
Approved WMORecruiting
Primary objectives: • To demonstrate reversal of the antiplatelet effects of ticagrelor after initiation of the intravenous (IV) infusion of PB2452 using the VerifyNow* PRUTest* (VerifyNow*, 2016) platelet function assay in ticagrelor-treated…